Summit Therapeutics (SUMM)

 

Latest News

Summit Therapeutics to Present at the Biotech Showcase

Summit Therapeutics to Present at the Biotech Showcase Summit Therapeutics plc ("Summit", or the "Company") SUMMIT THERAPEUTICS TO PRESENT AT THE BIOTECH SHOWCASE Oxford, UK, 9 January 2018 - Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), the drug discovery and development company advancing therapies for rare diseases ...

Summit in £10m antibiotics R&D deal

Summit Therapeutics is to pay 10m in cash and shares for Discuva whose principal asset is a genetics-based technology plat...

Acquisition of Discuva Ltd

RNS Number: 2793A Summit Therapeutics PLC 27 December 2017 Summit Therapeutics plc ('Summit' or the 'Company') SUMMIT OBTAINS INNOVATIVE ANTIBIOTIC DISCOVERY AND DEVELOPMENT PLATFORM THROUGH ACQUISITION OF DISCUVA LTD Positions Summit as a Leader in Research & Development of New Classes of Antibiotics En...

Summit enters licence agreement in Latin America

Summit Therapeutics, a drug discovery and development company, has entered into an exclusive licence and commerciali...

All News

DateHeadlineSource
09-01-18Summit Therapeutics to Present at the Biotech ShowcaseRNS
27-12-17Summit in £10m antibiotics R&D dealStockMarketWire
27-12-17Acquisition of Discuva LtdRNS
21-12-17Summit enters licence agreement in Latin AmericaStockMarketWire
21-12-17Summit Enters Licence and Commercialisation Agreement with Eurofarma for Latin American Rights to RidinilazoleRNS
06-12-17Summit Therapeutics plc : 3rd Quarter ResultsRNS
06-12-17Summit, Santhera, Catabasis and Duchenne UK to Host DMD Awareness DayRNS
04-12-17Summit schedules interim results announcementStockMarketWire
04-12-17Summit Therapeutics plc : Notice of Third Quarter ResultsRNS
22-11-17Summit to participate in US investor conferencesStockMarketWire
22-11-17Summit Therapeutics to Participate in Upcoming Investor ConferencesRNS
20-11-17Summit completes initial PhaseOut DMD trialStockMarketWire
20-11-17Summit Completes Initial 24 Weeks of Dosing of Ezutromid in Patients with DMD in PhaseOut DMD Clinical TrialRNS
16-11-17Summit Therapeutics plc : MiscellaneousRNS
09-11-17Summit to present at Duchenne ConferenceStockMarketWire
09-11-17Summit Highlights Utrophin Modulation as a Potential Universal Treatment Option in DMD at Action DuchenneRNS
06-11-17Summit inks revenue sharing agreement with Wellcome TrustStockMarketWire
06-11-17Summit Therapeutics Announces Revenue Sharing Agreement with Wellcome TrustRNS
25-10-17Summit Therapeutics plc : Grant of share optionsRNS
23-10-17Summit Therapeutics plc : Block listing applicationRNS
13-10-17Summit Therapeutics plc : Holding(s) in CompanyRNS
09-10-17Summit highlights Microbiome Preservation during Ridinilazole treatmentStockMarketWire
09-10-17Summit Highlights Microbiome Preservation During Ridinilazole Treatment at ID Week 2017RNS
05-10-17Summit Therapeutics plc : Exercise of OptionsRNS
04-10-17Summit to present at conference in Saint-MaloStockMarketWire
04-10-17Summit Highlights DMD Biomarker Validation Data at 22nd WMS CongressRNS
03-10-17Summit Therapeutics plc : Exercise of OptionsRNS
02-10-17Summit to host R&D dayStockMarketWire
02-10-17Summit Therapeutics to Host R&D Day 11 October 2017RNS
29-09-17Summit Therapeutics plc : Exercise of Share OptionsRNS
29-09-17Best AIM companies of 2017 Interactive Investor
28-09-17Summit Therapeutics plc : Exercise of Share OptionsRNS
25-09-17Summit joins cTAPStockMarketWire
25-09-17Summit Joins cTAP in Effort to Enhance Development of Utrophin Modulators and Other Treatments for DMDRNS
21-09-17Summit Therapeutics plc : Holding(s) in CompanyRNS
20-09-17Summit Therapeutics plc : Holding(s) in CompanyRNS
18-09-17Summit Therapeutics Announces Closing of its ADS Public Offering Raising USD20.1M Before ExpensesRNS
15-09-17Summit Therapeutics Announces Exercise of Underwriters' Over-Allotment OptionRNS
14-09-17Summit Announces Underwritten Public Offering of 1,459,000 ADSs to Raise USD17.5 Million Before ExpensesRNS
11-09-17Summit awarded Barda contract worth up to $62mStockMarketWire

RSS feeds

  • Editorial news feed for LSE:SUMM Editorial
  • Regulatory news feed for LSE:SUMM Regulatory

Join interactive investor

  • £22.50 fixed quarterly charge includes £22.50 in trading credits
  • £10 per trade or £6 for frequent traders
  • No % platform fees
  • £1 per trade for regular investment or dividend reinvestment

Open an account